BlackRock Fund Advisors’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$57.5M Buy
1,173,660
+137,064
+13% +$6.34M 0.01% 1590
2016
Q3
$49.6M Buy
1,036,596
+93,300
+10% +$4.61M 0.01% 1585
2016
Q2
$50.6M Buy
943,296
+12,490
+1% +$588K 0.01% 1483
2016
Q1
$41.6M Sell
930,806
-21,925
-2% -$889K 0.01% 1564
2015
Q4
$36.4M Buy
952,731
+43,737
+5% +$1.67M 0.01% 1694
2015
Q3
$28.9M Buy
908,994
+33,386
+4% +$1.16M 0.01% 1770
2015
Q2
$28.9M Sell
875,608
-16,988
-2% -$606K 0.01% 1887
2015
Q1
$36.7M Buy
892,596
+60,739
+7% +$2.46M 0.01% 1715
2014
Q4
$33.9M Buy
831,857
+74,972
+10% +$2.93M 0.01% 1738
2014
Q3
$27.7M Buy
756,885
+65,271
+9% +$2.82M 0.01% 1757
2014
Q2
$32M Buy
691,614
+22,987
+3% +$1.02M 0.01% 1706
2014
Q1
$27.5M Buy
668,627
+7,990
+1% +$297K 0.01% 1824
2013
Q4
$25.2M Buy
660,637
+319,875
+94% +$9.87M 0.01% 1845
2013
Q3
$8.14M Buy
340,762
+37,605
+12% +$844K ﹤0.01% 2501
2013
Q2
$5.15M Buy
+303,157
New +$4.37M ﹤0.01% 2665

Other funds holding ANIK

BlackRock Fund Advisors's ANIK Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Anika Therapeutics (ANIK) stake by 13% in Q4 2016, buying an estimated $6.34M and bringing the position to 1,173,660 shares worth $57.5M. The position accounts for 0.01% of the portfolio, ranked #1590.

BlackRock Fund Advisors first reported a position in ANIK in Q2 2013 and has held it in 15 quarters since. 158 funds tracked by Wall St. Rank hold ANIK as of Q4 2016.

  • BlackRock Fund Advisors held 1,173,660 shares of Anika Therapeutics worth $57.5M as of Q4 2016.
  • BlackRock Fund Advisors bought 137,064 Anika Therapeutics shares in Q4 2016, an estimated $6.34M.
  • Anika Therapeutics made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1590 holding.
  • BlackRock Fund Advisors first reported a position in Anika Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • 158 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.